Depth-resolved Quantitative Multi-Modal Imaging for GI Cancer Detection
用于胃肠道癌症检测的深度分辨定量多模态成像
基本信息
- 批准号:8250371
- 负责人:
- 金额:$ 21.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelBiological MarkersBiometryCancer DetectionCancer DiagnosticsClinicClinicalCollaborationsDataDetectionDevelopmentDiagnosisDiagnosticDiagnostic ImagingDoctor of PhilosophyDysplasiaEarly DiagnosisEndoscopyEnzymesEpithelialEpitheliumExcisionExcision biopsyFluorescenceGastroenterologyGastrointestinal tract structureGenerationsGoldHistopathologyImageImaging technologyLesionLightLiteratureMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMetaplasiaModalityMolecularMorphologyMucous MembraneNuclearOptical Coherence TomographyOptical TomographyPathologyPatientsPeptide HydrolasesPrincipal InvestigatorPublishingQualifyingResearchResolutionSampling ErrorsScreening for cancerSensitivity and SpecificitySurfaceTechnologyTestingTextureTherapeuticTimeTissuesTranslatingUp-Regulationbasecancer diagnosiscancer riskcancer therapydiagnostic accuracyexperiencegastrointestinalimprovedin vivomolecular imagingneoplasticnovelnovel diagnosticsoptical imagingoutcome forecastpublic health relevancereceptor expressiontechnology developmenttooltumor progression
项目摘要
DESCRIPTION (provided by applicant): Early detection of neoplastic changes remains a critical challenge in clinical cancer diagnosis and treatment. Many cancers arise from epithelial layers such as those of the gastrointestinal (GI) tract. White-light endoscopy guided excisional biopsy and histopathology is currently the gold standard for GI cancer diagnosis. However, it suffers from high false negative rates due to the sampling errors. Furthermore, a significant portion (~10%- 30%) of patients after endoscopic ablative therapeutic treatment showed the presence of metaplasia or dysplasia buried underneath the neo-epithelium, which is associated with the risk of cancer development. Current standard endoscopic technology is unable to detect those subsurface lesions. Therefore, there is a critical need for developing new diagnostic tools which can assess tissue architectural and molecular information across the mucosal depth for improved detection of subsurface cancer, and evaluate the invasion depth of a lesion. Since cancer development is associated with in both morphological and molecular alterations, an imaging technology that can quantitative image tissue's morphological and molecular biomarkers and assess the depth- extent of a lesion in vivo and in real time, without the need for tissue excision, would be a major advance in GI cancer diagnostics and therapy. The objective of this application is to develop a new generation of multi-modal depth-resolved imaging technology for GI cancer detection. This proposal is built upon our novel multi-modal optical imaging platform combining high-resolution optical coherence tomography (OCT) and depth-resolved high-sensitivity fluorescence laminar optical tomography (FLOT) for simultaneous structural and molecular imaging. Our extensive preliminary data on multi-modal imaging of animal models demonstrates the feasibility for simultaneous quantitative imaging of structural and molecular information for more accurate diagnosis and prognosis. To establish the diagnostic ability of OCT/FLOT for GI cancer detection, we propose to pursue an Exploratory/Developmental Research (R21) to pursue three specific aims: 1) Image an animal model of GI cancer using OCT/FLOT and obtain the correlated histopathological diagnosis. 2) Develop quantitative structural and molecular imaging parameters from co-registered OCT/FLOT images for multi-parametric analysis. 3) Establish the sensitivity, specificity, and diagnostic accuracy of OCT/FLOT for GI cancer detection, and test the hypothesis of enhanced cancer detection using combined information compared to single modality alone. If successful, this project will result in a fundamentally new non-invasive multi-modal imaging technology for improved GI cancer detection, which can be readily translated into endoscopic imaging in the GI clinics. It is expected to have a major impact on detection, diagnosis, and characterization of GI cancers, as well as a wide range of epithelial cancers.
PUBLIC HEALTH RELEVANCE: Early detection of neoplastic changes especially those buried underneath the surface remains a critical challenge in clinical cancer diagnosis and treatment of the gastrointestinal (GI) tract. The objective of this application is to develop a new generation of multi-modal depth-resolved imaging technology for depth- resolved structural and molecular imaging for enhanced GI cancer detection. If successful, this project will result in a new non-invasive multi-modal imaging technology that can be readily translated into endoscopic imaging of GI cancers, as well as a wide range of epithelial cancers.
描述(由申请人提供):肿瘤变化的早期检测仍然是临床癌症诊断和治疗的关键挑战。许多癌症起源于上皮层,例如胃肠道(GI)的上皮层。白光内窥镜引导的切除活检和组织病理学是目前胃肠道癌症诊断的金标准。然而,由于采样误差,它遭受高假阴性率。此外,在内镜消融治疗后,相当一部分(约10%- 30%)患者显示存在埋藏在新上皮下的化生或异型增生,这与癌症发展风险相关。目前的标准内窥镜技术无法检测到这些表面下病变。因此,迫切需要开发新的诊断工具,其可以评估跨粘膜深度的组织结构和分子信息,以改善对表面下癌症的检测,并评估病变的侵入深度。 由于癌症发展与形态学和分子学改变相关,因此能够对组织的形态学和分子生物标志物进行定量成像并在体内和真实的时间内评估病变的深度-范围而不需要组织切除的成像技术将是GI癌症诊断和治疗的重大进步。本申请的目的是开发新一代用于GI癌症检测的多模态深度分辨成像技术。该建议是建立在我们的新型多模态光学成像平台结合高分辨率光学相干断层扫描(OCT)和深度分辨高灵敏度荧光层状光学断层扫描(FLOT)的同时结构和分子成像。我们对动物模型的多模态成像的广泛初步数据证明了同时定量成像结构和分子信息的可行性,以获得更准确的诊断和预后。为了建立OCT/FLOT对GI癌症检测的诊断能力,我们建议进行探索性/开发性研究(R21),以实现三个特定目标:1)使用OCT/FLOT对GI癌症动物模型进行成像,并获得相关的组织病理学诊断。2)从共配准OCT/FLOT图像中开发定量结构和分子成像参数,用于多参数分析。3)建立OCT/FLOT用于GI癌症检测的灵敏度、特异性和诊断准确性,并测试与单一模态相比使用组合信息增强癌症检测的假设。如果成功,该项目将产生一种全新的非侵入性多模态成像技术,用于改善GI癌症检测,该技术可以很容易地转化为GI诊所的内窥镜成像。预计它将对GI癌症以及各种上皮癌的检测、诊断和表征产生重大影响。
公共卫生相关性:早期发现肿瘤变化,特别是那些隐藏在表面之下的肿瘤变化仍然是临床癌症诊断和胃肠道(GI)治疗的关键挑战。本申请的目的是开发新一代多模态深度分辨成像技术,用于深度分辨结构和分子成像,以增强GI癌症检测。如果成功,该项目将产生一种新的非侵入性多模态成像技术,可以很容易地转化为胃肠道癌症以及各种上皮癌的内窥镜成像。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Optical tecnology developments in biomedicine: history, current and future.
生物医学光学技术的发展:历史、当前和未来。
- DOI:
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:Nioka,Shoko;Chen,Yu
- 通讯作者:Chen,Yu
A forward-imaging needle-type OCT probe for image guided stereotactic procedures.
- DOI:10.1364/oe.19.026283
- 发表时间:2011-12-19
- 期刊:
- 影响因子:3.8
- 作者:Liang CP;Wierwille J;Moreira T;Schwartzbauer G;Jafri MS;Tang CM;Chen Y
- 通讯作者:Chen Y
In vivo, label-free, three-dimensional quantitative imaging of kidney microcirculation using Doppler optical coherence tomography.
- DOI:10.1038/labinvest.2011.112
- 发表时间:2011-11
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yu Chen其他文献
Yu Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yu Chen', 18)}}的其他基金
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma
定义组蛋白 H3K4 单甲基转移酶功能障碍在尿路上皮癌中的作用
- 批准号:
10522552 - 财政年份:2022
- 资助金额:
$ 21.17万 - 项目类别:
Automatic Wide-Field Optical Coherence Tomography for Assessment of Transplant Kidney Viability
用于评估移植肾活力的自动广域光学相干断层扫描
- 批准号:
10501992 - 财政年份:2022
- 资助金额:
$ 21.17万 - 项目类别:
Evolution and inhibition of carbapenemase in beta-lactam resistance
β-内酰胺耐药中碳青霉烯酶的进化和抑制
- 批准号:
10598501 - 财政年份:2021
- 资助金额:
$ 21.17万 - 项目类别:
Evolution and inhibition of carbapenemase in beta-lactam resistance
β-内酰胺耐药中碳青霉烯酶的进化和抑制
- 批准号:
10385772 - 财政年份:2021
- 资助金额:
$ 21.17万 - 项目类别:
Patient-Derived Models of Prostate Cancer for Personalized Medicine
用于个体化医疗的前列腺癌患者衍生模型
- 批准号:
10472536 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Patient-Derived Models of Prostate Cancer for Personalized Medicine
用于个体化医疗的前列腺癌患者衍生模型
- 批准号:
10219178 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Patient-Derived Models of Prostate Cancer for Personalized Medicine
用于个体化医疗的前列腺癌患者衍生模型
- 批准号:
10683753 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance
了解异常肝核转录回路在前列腺癌肿瘤发生和去势抵抗中的作用
- 批准号:
10224110 - 财政年份:2017
- 资助金额:
$ 21.17万 - 项目类别:
相似海外基金
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10490338 - 财政年份:2021
- 资助金额:
$ 21.17万 - 项目类别:
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10353104 - 财政年份:2021
- 资助金额:
$ 21.17万 - 项目类别:
Investigating pollution dynamics of swimming pool waters by means of chemical and biological markers
利用化学和生物标记物研究游泳池水体的污染动态
- 批准号:
21K04320 - 财政年份:2021
- 资助金额:
$ 21.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10688286 - 财政年份:2021
- 资助金额:
$ 21.17万 - 项目类别:
Novel biological markers for immunotherapy and comprehensive genetic analysis in thymic carcinoma
用于胸腺癌免疫治疗和综合遗传分析的新型生物标志物
- 批准号:
20K17755 - 财政年份:2020
- 资助金额:
$ 21.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10578649 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10295141 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10041708 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
9776149 - 财政年份:2019
- 资助金额:
$ 21.17万 - 项目类别:
Combining biological and non-biological markers to develop a model predictive of treatment response for individuals with depression
结合生物和非生物标志物来开发预测抑郁症患者治疗反应的模型
- 批准号:
2063934 - 财政年份:2018
- 资助金额:
$ 21.17万 - 项目类别:
Studentship